#United States #New York #TransMedics #Nasdaq TMDX #investor events

TransMedics Group to Host Investor & Analyst Day

TransMedics Group, Inc. (Nasdaq: TMDX), a company revolutionizing organ transplant therapies, has announced an upcoming Investor & Analyst Day scheduled for December 10, 2024. The event will take place at 10 AM ET in New York City. This gathering presents a unique opportunity for investors and analysts to engage directly with TransMedics’ leadership team.

Event Overview

Waleed Hassanein, MD, President and CEO of TransMedics, along with key members of the leadership team, will outline the firm’s growth strategies, clinical developments, and operational advancements. Participants will gain valuable insights into how TransMedics is poised to change the landscape of organ transplantation for patients suffering from end-stage heart, lung, and liver failure.

The company has been a pioneer in the rent of portable extracorporeal warm perfusion technology, ensuring better outcomes for transplanted organs. Following the presentations, a question-and-answer session will allow attendees to engage with the management team; however, questions will only be entertained from those present in the live audience.

Registration Details

For those wishing to attend in person, advanced registration is required. Interested individuals must contact Laine Morgan at [email protected] before December 4, 2024, to secure their place and receive further information about the event.

In addition, a live and archived webcast of the presentations will be accessible for broader audiences on the 'Investors' section of the TransMedics website. This will allow even those unable to attend in person to stay updated on the company's developments and strategic direction.

About TransMedics Group

Founded to address a critical need for high-quality donor organs, TransMedics Group is headquartered in Andover, Massachusetts. Its innovative methods aim to enhance organ preservation, assess their viability, and ultimately increase the number of available organs for transplantation. The company's dedication is to find better solutions to extend the lives of patients facing severe organ failures, highlighting its position as a leader in transplant technologies.

As the date approaches, industry experts and investors alike are watching closely for what insights and future plans TransMedics will unveil at this event. The significance of organ transplant technologies cannot be overstated, and with TransMedics at the forefront, the future looks promising.

This function not only elucidates the company's efforts but also serves to reaffirm its commitment to transforming healthcare standards concerning organ transplantation.

For more information and updates leading to the Investor & Analyst Day, participants are encouraged to keep an eye on the TransMedics website as well as their official communications. Stay tuned for what could potentially be a milestone day in the medical technology landscape.